Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3H0IX)

Drug Name

AMG 890 Drug Info

Synonyms

Olpasiran

Indication

Disease Entry	ICD 11	Status	REF
Cardiac fibrosis	DB98.8	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Apolipoprotein A messenger RNA (LPA mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pelacarsen	DMY757D	Cardiovascular disease	BA00-BE2Z	Phase 3	[3]
ISIS-APO(a)	DMQ3C05	Coronary artery disease	BA80	Phase 2	[4]
SLN360	DMVVU4V	Hyperlipidemia	5C80.Z	Phase 2	[5]
LY3819469	DMUDNNF	Elevated Lipoprotein(a)	5C80.1	Phase 2	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Apolipoprotein A messenger RNA (LPA mRNA)	TTU9LGY	APOA_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04270760) Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Amgen.
3	Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol. 2022 Jul 1;7(7):760-769.
4	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
5	Recent lipoprotein(a) trials. Curr Opin Lipidol. 2022 Dec 1;33(6):301-308.
6	ClinicalTrials.gov (NCT05565742) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a). U.S.National Institutes of Health.